Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETEC + rCTB
- Development stage
- Phase 3
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
A combination therapy consisting of Enterotoxigenic Escherichia coli (ETEC) components and recombinant Cholera Toxin B subunit (rCTB). This combination likely functions as a vaccine or therapeutic approach targeting gastrointestinal infections. The rCTB component may serve dual purposes as both an antigen and an adjuvant to enhance immune response against ETEC.
02
Targets
Host intestinal epithelial receptors for Enterotoxigenic Escherichia coli colonization factorsGM1 (GM1 ganglioside)
Beyond the preview
Go deeper on ETEC + rCTB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETEC + rCTB.